Anemia control in renal transplant recipients receiving continuous erythropoietin receptor activator (C.E.R.A.) treatment: the AnemiaTrans Study.

Introduction: Continuous erythropoietin receptor activator (C.E.R.

Satisfaction and adherence with immunosuppressant treatment in renal transplant patients living with a working graft.

Background: The aim of this study was to analyze patient satisfaction and adherence in a sample of renal transplant patients living with a working allograft.

Methods: An epidemiological cross-sectional multicenter study was carried out with renal recipients who had received a transplant 6-24 months before and were undergoing immunosuppressant therapy (IT). Sociodemographic and clinical variables registered were dosage, allograft functioning, number of medications, health-related quality of life (HRQoL by SF-6D), patients' satisfaction (SAT-Q) and adherence to medication (abnormal levels of immunosuppressant in blood tests [ALIBT] and clinical impression).